In vivo Drug Efficacy Monitoring

In Vivo Monitoring of Drug Efficacy & Action

• IVIM Technology’s contract R&D service provides a direct imaging analysis of delivery to target tissue and cells, efficacy, and mode of action (MOA) of new therapeutic candidates in microscopic cellular-level in various preclinical model of human disease.

Therapeutic Candidates Facilitating or Inhibiting Angiogenesis Vessel normalization by anti-angiogenic therapeutic candidates

• Disease model : Tumor, acute/chronic inflammation, retinopathy, etc.
• Therapeutic candidates : Anti-tumor, anti-inflammatory drug, etc.
• Observations : Changes in vessel morphology, vessel diameter, vessel density, vascular permeability, blood flow rate, etc.

Tumor

Vehicle, Day 7

Vessel

Lung cancer cell

Vehicle, Day 13

Tumor

Drug, Day 7

Vessel

Lung cancer cell

Drug, Day 13

Angiogenesis in target cell transplanted site or ischemic regions

• Disease model : Ischemia-reperfusion injury model, islet cell/stem cell transplantation model, etc.

Kidney

Vessel

Islet graft

Anti-inflammatory Therapeutic Candidates Efficacy monitoring & MOA validation of anti-inflammatory therapeutic candidates

• Disease model : Acute/chronic inflammation model, tumor model, etc.
• Observations : Changes in microcirculation, tissue cell apoptosis, immune cell recruitment/motility/activity (phagocytosis), etc.
• Tissue cells : Vascular endothelial cells, lymphatic endothelial cell, hepatocyte, kidney cell, astrocyte, etc.
• Immune cells : Granulocyte, macrophage, neutrophil, dendritic cell, monocyte, microglial cell, NK cell, etc.

Real-time imaging of dynamic phenotype changes by treatment of therapeutic candidates

Pre-Drug

Neutrophil

RBC

Vessel

Post-Drug

Pre-Drug

RBC

Post-Drug

Quantitative comparison of groups

Lung

Sham

Merge

Neutrophil

RBC

Vessel

Vehicle

Merge

Neutrophil

RBC

Vessel

Drug

Merge

Neutrophil

RBC

Vessel

Efficacy Monitoring of Other Therapeutic Candidates Changes in tumor cell growth/death/metastasis after treatment of anti-tumor therapeutic candidates
Changes in fibrotic collagen deposition & immune cell recruitment after treatment of anti-fibrotic therapeutic candidates
Changes in drug delivery, uptake & absorption